InvestSMART

Cryosite Limited (ASX:CTE)

ALERT: Price-sensitive ASX Announcement for CTE
Current share price for CTE : $1.200 0.32 (36.36%)+
Announcement
Release
13 Oct 2025 10:01AM
Price at Release
$0.880
Full Release
download
Summary
Cryosite Limited provided a trading update for the first quarter of the fiscal year 2026, showing strong financial performance with a 22% increase in revenue compared to the previous year. The company's EBITDA rose by 41%, and its net profit after tax (NPAT) increased by 59%. Growth was driven by high demand across Cryosite's Ambient, Cold, and Frozen segments, alongside robust performance in the Ultra-Frozen and Cryogenic segment, particularly in cell and gene therapies and mRNA-based medicines. The company also reported progress on its new warehouse facility at Adderley St, Auburn, which is expected to enhance operational capacity and improve service offerings. Additionally, Cryosite's Cord Blood business continues to generate increasing cash revenues as legacy contracts expire and new agreements are established on an annual basis. The company enters the second quarter with positive momentum and a focus on scaling its operations.
Key Points
  • Revenue increased by 22% to $3.9 million in Q1 FY26.
  • EBITDA rose by 41% to $1.0 million.
  • NPAT increased by 59% to $0.6 million.
  • Growth driven by demand in Ambient, Cold, and Frozen segments.
  • Robust performance in Ultra-Frozen and Cryogenic segment.
  • Progress on new warehouse facility at Adderley St, Auburn.
  • Cord Blood business revenues continue to increase.
  • Positive momentum entering Q2 FY26.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.